title: A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy.
abstract: Primary neuroendocrine breast carcinoma (NEBC) is a very rare type of breast cancer. Two characteristic biomarkers, namely, CgA and Syn, should be immunohistochemically detected to diagnose NEBC. In this study, a 43-year-old woman with a large mass of 8.3 cm × 2.9 cm in her right breast was reported. The patient was pathologically diagnosed with NEBC after specific markers, including CgA and Syn, as well as few differential markers, such as CK7, ER, PR, C-erbB-2, NSE, and E-cadherin, were immunohistochemically detected. The patient showed a remarkable response to four cycles of neo-adjuvant chemotherapy (partial response based on RECIST criteria) and sequentially underwent modified radical mastectomy. Moreover, the diagnosis and treatment of NEBC based on this case and available related literature were discussed.
authors.affiliation: Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou, 515031, China.
authors.forename: Xiaolong
authors.initials: X
authors.lastname: Wei
authors.forename: Chunfa
authors.initials: C
authors.lastname: Chen
authors.forename: Didi
authors.initials: D
authors.lastname: Xi
authors.forename: Jinwen
authors.initials: J
authors.lastname: Bai
authors.forename: Wenhe
authors.initials: W
authors.lastname: Huang
authors.forename: Luoxiang
authors.initials: L
authors.lastname: Rong
authors.forename: Mingyao
authors.initials: M
authors.lastname: Wu
authors.forename: Guojun
authors.initials: G
authors.lastname: Zhang
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018278:Carcinoma, Neuroendocrine / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D053379:Chromogranin A / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008327:Mammography / Q000379:methods; D015411:Mastectomy, Modified Radical / Q000379:methods*; D016708:Synaptophysin / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D053379:Chromogranin A; D016708:Synaptophysin
references.citation: Histopathology. 2002 Mar;40(3):211-4
references.pmid: 11895485
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Histopathology. 1982 Sep;6(5):549-69
references.pmid: 6183185
references.citation: Breast Cancer. 2007;14(2):250-3
references.pmid: 17485914
references.citation: Semin Diagn Pathol. 1989 May;6(2):174-88
references.pmid: 2503862
references.citation: Verh Dtsch Ges Pathol. 2002;86:116-9
references.pmid: 12647359
references.citation: Coll Antropol. 2012 Sep;36(3):1053-5
references.pmid: 23213972
references.citation: Ann Ital Chir. 2013 Jan-Feb;84(1):81-5
references.pmid: 22672972
references.citation: Semin Diagn Pathol. 2000 May;17(2):127-37
references.pmid: 10839613
references.citation: Frankf Z Pathol. 1963 Oct 3;73:24-39
references.pmid: 14097474
references.citation: Am J Clin Pathol. 1987 Aug;88(2):146-52
references.pmid: 3618548
references.citation: Am J Clin Pathol. 1979 Dec;72(6):909-16
references.pmid: 229725
references.citation: Virchows Arch. 1994;425(5):449-57
references.pmid: 7850068
references.citation: Clin Breast Cancer. 2009 Aug;9(3):189-92
references.pmid: 19661045